Especially, that for several driver mutations (e.g., EGFR, ALK, ROS-1, KRAS, EML4-ALK mutations in ADC; NRF2 mutation in SCC or cMYC overexpression and inactivation of TP53 via mutations in both subtypes), targeted therapies have been developed [2,3]. This evidence concerns the gene ROS1 and AIDS dementia complex.